Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Zanubrutinib + Rituximab for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a new combination drug therapy for people with leukemia or lymphoma who haven't received treatment before. The therapy consists of two drugs: zanubrutinib and rituximab. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The study is being done to find out if zanubrutinib combined with rituximab can help control previously untreated chronic lymphocytic leukemia or small lymph
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service